The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Addition of tyrosine kinase inhibitors (TKIs) in patients (pts) with unresectable hepatocellular carcinoma (HCC) who progress on first-line immunotherapy (IO).
 
Linda Wu
No Relationships to Disclose
 
Roger Esteban
No Relationships to Disclose
 
Michelle Rudshteyn
No Relationships to Disclose
 
Myron E. Schwartz
Research Funding - Bristol-Myers Squibb
 
Max W. Sung
Consulting or Advisory Role - Eisai; Genentech
 
Josep M Llovet
Consulting or Advisory Role - AstraZeneca; Bayer; Boston Scientific; Bristol Myers Squibb; Eisai; Genentech; Glycotest; Ipsen; Iylon; Lilly; Merck; Mina Alpha Ltd; Nucleix; Omega Therapeutics; Roche
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer
 
Deirdre Jill Cohen
Consulting or Advisory Role - Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst)